S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:EXPO

Exponent Competitors

$93.24
+1.06 (+1.15 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$91.20
Now: $93.24
$93.36
50-Day Range
$83.10
MA: $89.63
$96.78
52-Week Range
$58.03
Now: $93.24
$97.84
Volume279,952 shs
Average Volume238,765 shs
Market Capitalization$4.81 billion
P/E Ratio62.16
Dividend Yield0.82%
Beta0.32

Competitors

Exponent (NASDAQ:EXPO) Vs. VRSK, EFX, NLSN, FCN, ICFI, and CBZ

Should you be buying EXPO stock or one of its competitors? Companies in the sub-industry of "research & consulting services" are considered alternatives and competitors to Exponent, including Verisk Analytics (VRSK), Equifax (EFX), Nielsen (NLSN), FTI Consulting (FCN), ICF International (ICFI), and CBIZ (CBZ).

Verisk Analytics (NASDAQ:VRSK) and Exponent (NASDAQ:EXPO) are both business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

88.2% of Verisk Analytics shares are held by institutional investors. Comparatively, 90.3% of Exponent shares are held by institutional investors. 2.6% of Verisk Analytics shares are held by company insiders. Comparatively, 2.2% of Exponent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Verisk Analytics and Exponent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verisk Analytics15702.46
Exponent01202.67

Verisk Analytics currently has a consensus price target of $191.25, suggesting a potential downside of 0.78%. Exponent has a consensus price target of $89.00, suggesting a potential downside of 4.55%. Given Verisk Analytics' higher possible upside, analysts plainly believe Verisk Analytics is more favorable than Exponent.

Dividends

Verisk Analytics pays an annual dividend of $1.08 per share and has a dividend yield of 0.6%. Exponent pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. Verisk Analytics pays out 24.7% of its earnings in the form of a dividend. Exponent pays out 49.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Verisk Analytics and Exponent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verisk Analytics19.12%36.42%11.46%
Exponent19.63%23.66%15.24%

Volatility & Risk

Verisk Analytics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Exponent has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

Earnings & Valuation

This table compares Verisk Analytics and Exponent's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verisk Analytics$2.61 billion12.02$449.90 million$4.3844.01
Exponent$417.20 million11.54$82.46 million$1.5360.94

Verisk Analytics has higher revenue and earnings than Exponent. Verisk Analytics is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Summary

Verisk Analytics beats Exponent on 10 of the 16 factors compared between the two stocks.

Equifax (NYSE:EFX) and Exponent (NASDAQ:EXPO) are both business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Equifax and Exponent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Equifax11.29%29.20%9.34%
Exponent19.63%23.66%15.24%

Analyst Ratings

This is a summary of current ratings and target prices for Equifax and Exponent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Equifax08802.50
Exponent01202.67

Equifax currently has a consensus target price of $178.3667, suggesting a potential downside of 0.21%. Exponent has a consensus target price of $89.00, suggesting a potential downside of 4.55%. Given Equifax's higher probable upside, analysts clearly believe Equifax is more favorable than Exponent.

Valuation & Earnings

This table compares Equifax and Exponent's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Equifax$3.51 billion6.20$-398,800,000.00$5.6231.80
Exponent$417.20 million11.54$82.46 million$1.5360.94

Exponent has lower revenue, but higher earnings than Equifax. Equifax is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Dividends

Equifax pays an annual dividend of $1.56 per share and has a dividend yield of 0.9%. Exponent pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. Equifax pays out 27.8% of its earnings in the form of a dividend. Exponent pays out 49.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Equifax is clearly the better dividend stock, given its higher yield and lower payout ratio.

Institutional & Insider Ownership

91.5% of Equifax shares are owned by institutional investors. Comparatively, 90.3% of Exponent shares are owned by institutional investors. 0.9% of Equifax shares are owned by company insiders. Comparatively, 2.2% of Exponent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Equifax has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Exponent has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

Summary

Equifax beats Exponent on 9 of the 16 factors compared between the two stocks.

Nielsen (NYSE:NLSN) and Exponent (NASDAQ:EXPO) are both mid-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Nielsen and Exponent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nielsen-2.38%22.28%3.45%
Exponent19.63%23.66%15.24%

Valuation and Earnings

This table compares Nielsen and Exponent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nielsen$6.50 billion1.19$-415,000,000.00$1.6912.86
Exponent$417.20 million11.54$82.46 million$1.5360.94

Exponent has lower revenue, but higher earnings than Nielsen. Nielsen is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Nielsen and Exponent, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nielsen03602.67
Exponent01202.67

Nielsen currently has a consensus price target of $20.7273, indicating a potential downside of 4.61%. Exponent has a consensus price target of $89.00, indicating a potential downside of 4.55%. Given Exponent's higher possible upside, analysts plainly believe Exponent is more favorable than Nielsen.

Volatility & Risk

Nielsen has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Exponent has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Dividends

Nielsen pays an annual dividend of $0.24 per share and has a dividend yield of 1.1%. Exponent pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. Nielsen pays out 14.2% of its earnings in the form of a dividend. Exponent pays out 49.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Nielsen is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

90.3% of Exponent shares are held by institutional investors. 0.4% of Nielsen shares are held by insiders. Comparatively, 2.2% of Exponent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Exponent beats Nielsen on 9 of the 15 factors compared between the two stocks.

Exponent (NASDAQ:EXPO) and FTI Consulting (NYSE:FCN) are both mid-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Insider & Institutional Ownership

90.3% of Exponent shares are owned by institutional investors. Comparatively, 97.3% of FTI Consulting shares are owned by institutional investors. 2.2% of Exponent shares are owned by company insiders. Comparatively, 2.2% of FTI Consulting shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Exponent has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, FTI Consulting has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Exponent and FTI Consulting, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exponent01202.67
FTI Consulting00203.00

Exponent currently has a consensus target price of $89.00, suggesting a potential downside of 4.55%. FTI Consulting has a consensus target price of $171.00, suggesting a potential upside of 46.88%. Given FTI Consulting's stronger consensus rating and higher possible upside, analysts clearly believe FTI Consulting is more favorable than Exponent.

Earnings & Valuation

This table compares Exponent and FTI Consulting's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exponent$417.20 million11.54$82.46 million$1.5360.94
FTI Consulting$2.35 billion1.76$216.73 million$5.8020.07

FTI Consulting has higher revenue and earnings than Exponent. FTI Consulting is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exponent and FTI Consulting's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exponent19.63%23.66%15.24%
FTI Consulting7.56%13.27%7.18%

Summary

FTI Consulting beats Exponent on 7 of the 13 factors compared between the two stocks.

Exponent (NASDAQ:EXPO) and ICF International (NASDAQ:ICFI) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Exponent and ICF International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exponent01202.67
ICF International00403.00

Exponent currently has a consensus price target of $89.00, suggesting a potential downside of 4.55%. ICF International has a consensus price target of $91.40, suggesting a potential upside of 12.09%. Given ICF International's stronger consensus rating and higher possible upside, analysts clearly believe ICF International is more favorable than Exponent.

Dividends

Exponent pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. ICF International pays an annual dividend of $0.56 per share and has a dividend yield of 0.7%. Exponent pays out 49.7% of its earnings in the form of a dividend. ICF International pays out 13.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ICF International has increased its dividend for 1 consecutive years.

Profitability

This table compares Exponent and ICF International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exponent19.63%23.66%15.24%
ICF International4.19%10.77%4.85%

Valuation and Earnings

This table compares Exponent and ICF International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exponent$417.20 million11.54$82.46 million$1.5360.94
ICF International$1.48 billion1.04$68.94 million$4.1519.65

Exponent has higher earnings, but lower revenue than ICF International. ICF International is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.3% of Exponent shares are owned by institutional investors. Comparatively, 88.3% of ICF International shares are owned by institutional investors. 2.2% of Exponent shares are owned by company insiders. Comparatively, 4.3% of ICF International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Exponent has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, ICF International has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Summary

ICF International beats Exponent on 9 of the 17 factors compared between the two stocks.

Exponent (NASDAQ:EXPO) and CBIZ (NYSE:CBZ) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Exponent and CBIZ's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exponent$417.20 million11.54$82.46 million$1.5360.94
CBIZ$948.42 million1.56$70.71 million$1.2721.42

Exponent has higher earnings, but lower revenue than CBIZ. CBIZ is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Exponent and CBIZ, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exponent01202.67
CBIZ00103.00

Exponent presently has a consensus price target of $89.00, suggesting a potential downside of 4.55%. Given Exponent's higher probable upside, research analysts plainly believe Exponent is more favorable than CBIZ.

Profitability

This table compares Exponent and CBIZ's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exponent19.63%23.66%15.24%
CBIZ8.08%11.27%5.27%

Insider & Institutional Ownership

90.3% of Exponent shares are owned by institutional investors. Comparatively, 86.4% of CBIZ shares are owned by institutional investors. 2.2% of Exponent shares are owned by company insiders. Comparatively, 7.4% of CBIZ shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Exponent has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, CBIZ has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Summary

Exponent beats CBIZ on 10 of the 14 factors compared between the two stocks.


Exponent Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Verisk Analytics logo
VRSK
Verisk Analytics
1.9$192.76+1.1%$31.34 billion$2.61 billion61.78
Equifax logo
EFX
Equifax
1.6$178.74+0.1%$21.74 billion$3.51 billion49.79Analyst Report
Nielsen logo
NLSN
Nielsen
1.1$21.73+0.2%$7.76 billion$6.50 billion-51.74News Coverage
FTI Consulting logo
FCN
FTI Consulting
1.9$116.42+0.6%$4.15 billion$2.35 billion23.91
ICF International logo
ICFI
ICF International
2.1$81.54+0.8%$1.54 billion$1.48 billion25.32
CBIZ logo
CBZ
CBIZ
1.4$27.20+0.0%$1.48 billion$948.42 million19.57
Huron Consulting Group logo
HURN
Huron Consulting Group
1.5$58.30+3.6%$1.33 billion$965.47 million-291.49Analyst Report
News Coverage
CRA International logo
CRAI
CRA International
1.9$59.75+3.0%$464.62 million$451.37 million21.19
VSE logo
VSEC
VSE
1.7$41.39+3.0%$457.40 million$752.63 million413.94News Coverage
Franklin Covey logo
FC
Franklin Covey
1.5$24.96+1.9%$350.34 million$198.46 million-35.66
Acacia Research logo
ACTG
Acacia Research
0.9$5.74+6.4%$282.86 million$11.25 million47.83News Coverage
Mistras Group logo
MG
Mistras Group
1.7$8.49+3.2%$247.85 million$748.59 million-2.49
Odyssey Marine Exploration logo
OMEX
Odyssey Marine Exploration
0.5$7.01+1.6%$85.58 million$3.10 million-4.74High Trading Volume
News Coverage
This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.